Market Insight from

Teva and MedinCell looking to enter increasingly competitive LAI schizophrenia market

On 7 January, Teva Pharmaceuticals and MedinCell announced positive results from their Phase III trial (RISE Study) evaluating mdc-IRM (risperidone) as a maintenance treatment in adults and adolescents with schizophrenia.

Schizophrenia is a chronic progressive disorder; each relapse increases the burden of disease for patients and carers and has the potential to worsen long-term outcomes. In the RISE Study, participants treated with mdc-IRM saw a statistically significant increase in time to relapse compared to placebo.

Additionally, the safety profile was consistent with the known safety profile of other risperidone formulations. Teva Pharmaceuticals and MedinCell are now looking to the option of a new drug application based on the available clinical data.

Non-compliance is an important factor that can increase the risk of relapse in schizophrenia patients, and is one of the key challenges of treating schizophrenia. In order to try to increase compliance, an increasingly used strategy in the schizophrenia market is long-acting injectable (LAI) drugs, which have a favorable dosing strategy compared to oral therapies.

mdc-IRM is an extended-release injectable suspension for subcutaneous use, which can be administered once monthly or once every two months. In the RISE Study, patients treated with mdc-IRM administered once monthly and once every two months demonstrated a reduction of 80% and 62.5% in the risk to relapse compared to placebo, respectively.

Risperidone is one of the most widely-used antipsychotics for schizophrenia treatment, so if approved mdc-IRM is likely to see good uptake as physicians are highly familiar with risperidone, and it has a competitive edge of being the first risperidone formulation with a once every two months dosing regimen.

However, it will have to directly compete with Indivior’s Perseris (risperidone), an LAI with once-monthly dosing that launched in 2019 in the US and will have first-to-market advantage. GlobalData forecasts Perseris’ global sales to reach $173m in 2026.

As well as the other risperidone formulations, mdc-IRM will also face an increasingly competitive schizophrenia market with LAIs being developed for many of the other antipsychotic drugs used in schizophrenia treatment.

Of note, Janssen’s PP6M (paliperidone palmitate 6-monthly) is awaiting a decision from the European Medicines Agency (EMA), and if approved would be the first LAI schizophrenia treatment with a twice-yearly dosing regimen, giving it a big advantage over the LAIs with shorter dosing regimens, including mdc-IRM. GlobalData forecasts PP6M’s global sales to reach $5.3bn in 2026.

For pharmaceutical industry data, comment and analysis, visit GlobalData's Pharmaceuticals Intelligence Centre.

Go to article: Home | Catching the next Covid-19 variantGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Mettler Toledo Company InsightGo to article: Data Integrity Solutions – METTLER TOLEDOGo to article: CommentGo to article: New coronavirus variant causing concern as cases spike in South AfricaGo to article: Teva and MedinCell looking to enter LAI schizophrenia marketGo to article: Lack of injectable anti-HIV therapies in the Japanese marketGo to article: Prevention of thrombosis in Covid-19 patientsGo to article: T2D therapy accepted into FDA Emerging Technology ProgramGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: ButterworthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: Enter Amazon Pharmacy: the beginning of a great online pharmacy fight?Go to article: Covid-19 vaccines have made treating racism in medicine even more urgentGo to article: Could Covid-19 give pharma the chance for the ultimate image makeover?Go to article: Delivering a billion doses with the UK VMICGo to article: Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders GroupGo to article: Saxenda: profiling the first NHS weight loss drug for a decadeGo to article: How real-time genomic surveillance could spot new Covid-19 variantsGo to article: A new hope for slowing disability in MSGo to article: DatwylerGo to article: Datwyler Company Insight Go to article: ACG WorldwideGo to article: Gemini Data LoggersGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue